

O
MAR 14 2001
PATENT & TRADEMARK OFFICE

APR 12 2002

Attorney Docket No. PC10350AGPR

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
TECH CENTER 1600/2900

IN RE APPLICATION OF: Mark D. Fidock

APPLICATION NO.: 09/663,481

: Examiner: To be assigned

FILING DATE: September 15, 2000

: Group Art Unit: To be assigned

TITLE: Phosphodiesterase Enzymes

:

Hon. Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAR 20 2001

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

TECH CENTER 1600/2900

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.


The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Date: 3/14/01

Respectfully submitted,



Gregory P. Raymer
Attorney for Applicant(s)
Reg. No. 36,647

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 715-5746